It is a non-invasive molecular diagnostic platform based on the detection of a proprietary set of urinary biomarkers, specifically designed for bladder cancer.
It relies on the quantification of three microRNA (miRNA) profile systems and, in its most advanced version, also cytokines, to provide integrated solutions ranging from early diagnosis (BlaDimiR), to prediction of response to BCG immunotherapy (BlaDimiRplus), and to combined BCG and anti-PD-L1 therapies (BlaDimiRIO).
This precision technology enables more informed, personalized, and efficient clinical decision-making without the need for invasive procedures.
BlaDimiR, BlaDimiRplus & BaDimiRIO
Sample Collection: A urine sample is collected from the patient.
microRNA Analysis: The urine sample is analyzed to detect the presence and relative quantity of specific microRNAs. miRNAs are small RNA molecules that regulate gene expression, and their alteration may indicate the presence of cancer.
qPCR Technique: The detection and quantification of miRNAs is performed using real-time polymerase chain reaction (qPCR), a technique available in most laboratories.
Results Interpretation: A proprietary algorithm (risk calculator) analyzes the expression data of miRNAs and proteins. The risk calculator, associated with the three BlaDimiR tests, generates a personalized report in just a few minutes.
How BlaDimiR Works
Non-Invasive: Unlike cystoscopy, which is an invasive procedure, BlaDimiR uses a simple urine sample.
High Accuracy: BlaDimiR has demonstrated high sensitivity (90.5%) and specificity (97%) in detecting bladder cancer, resulting in a diagnostic accuracy of 96%.
Early Detection: It can detect bladder cancer in its early stages, which is crucial for effective treatment. BlaDimiR has shown diagnostic capability both in patients with a first-time suspicion of bladder cancer (incident cases) with 96% accuracy, and in those with a history of bladder cancer who present symptoms again (recurrent cases), with 95% accuracy.
Efficient Monitoring: It facilitates follow-up for patients who have already been treated, helping to detect recurrences early and less painfully
Treatment Response Prediction: BlaDimiRplus and BlaDimiRIO are companion diagnostic systems that predict the effectiveness of BCG therapy or the combination of BCG with anti-PD-L1, enabling better treatment selection for each patient and minimizing unnecessary side effects.
Advantages of BlaDimiR
Cost Reduction: By identifying which patients will benefit from BCG treatment or the combined BCG + anti-PD-L1 therapy, healthcare resources can be optimized more effectively.
Resource Optimization: Targeting BCG treatment to patients who are most likely to benefit helps maximize the efficiency of healthcare resource utilization.